Loading
A phase 2 trial of Zongertinib, Cisplatin, Carboplatin, Pemetrexed and Pembrolizumab in non-small-cell lung cancer, run by Boehringer Ingelheim, now recruiting.
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab is a phase 2 interventional study registered as NCT07486817 by Boehringer Ingelheim, with 60 participants planned, started 2026-06-04 and due to reach its primary completion in 2027-08-12. Interventions recorded: Zongertinib, Cisplatin, Carboplatin, Pemetrexed and Pembrolizumab.
Shares Zongertinib, Boehringer Ingelheim, Pemetrexed, Cisplatin and the tag pipeline.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.